OncoMatch/Clinical Trials/NCT05736965
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
Is NCT05736965 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Selinexor and Azacitidine for aml, adult.
Treatment: Selinexor · Azacitidine · Venetoclax — This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–4(Completely disabled)
Prior therapy
Cannot have received: anti-aml treatment
Exception: hydroxyurea
Lab requirements
Kidney function
creatinine clearance ≥ 30 mL/min (Cockroft-Gault formula)
Liver function
AST ≤ 3.0×ULN; ALT ≤ 3.0×ULN; Bilirubin ≤ 1.5×ULN (≤3.0×ULN if <75 years old); unless due to leukemic organ involvement
Liver function meets the following criteria: aspartate aminotransferase (AST) ≤ 3.0×ULN; alanine aminotransferase (ALT) ≤ 3.0×ULN; Bilirubin≤1.5×ULN; For subjects <75 years old, the bilirubin level can be ≤3.0×ULN; Unless due to leukemic organ involvement. Renal function meets the following criteria: creatinine clearance ≥ 30 mL/min (Cockroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify